

Guido Marcucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9619401/publications.pdf>

Version: 2024-02-01

167
papers

9,290
citations

76326

40
h-index

40979

93
g-index

168
all docs

168
docs citations

168
times ranked

10863
citing authors

#	ARTICLE	IF	CITATIONS
1	Spred1 deficit promotes treatment resistance and transformation of chronic phase CML. <i>Leukemia</i> , 2022, 36, 492-506.	7.2	5
2	Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. <i>Cancer</i> , 2022, 128, 529-535.	4.1	17
3	Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 111.e1-111.e8.	1.2	16
4	Roadmap on plasticity and epigenetics in cancer. <i>Physical Biology</i> , 2022, 19, 031501.	1.8	8
5	High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	4
6	Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent lbrutinib. <i>Bone Marrow Transplantation</i> , 2022, 57, 830-833.	2.4	2
7	Synergy of Venetoclax and 8-Chloro-Adenosine in AML: The Interplay of rRNA Inhibition and Fatty Acid Metabolism. <i>Cancers</i> , 2022, 14, 1446.	3.7	5
8	Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 368.e1-368.e7.	1.2	4
9	Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 1220-1226.	1.3	2
10	Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, 196, .	2.5	6
11	MicroRNA networks in FLT3-ITD acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2112482119.	7.1	5
12	Dynamic patterns of microRNA expression during acute myeloid leukemia state-transition. <i>Science Advances</i> , 2022, 8, eabj1664.	10.3	9
13	ILC1s control leukemia stem cell fate and limit development of AML. <i>Nature Immunology</i> , 2022, 23, 718-730.	14.5	22
14	Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E59-E63.	4.1	11
15	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e19-e25.	1.3	6
16	Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. <i>Blood</i> , 2021, 137, 471-484.	1.4	70
17	Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents. <i>American Journal of Hematology</i> , 2021, 96, E140-E143.	4.1	1
18	Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2285-2298.	7.2	10

#	ARTICLE	IF	CITATIONS
19	Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 255.e1-255.e9.	1.2	6
20	Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2021, 106, 851-858.	2.2	2
21	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021, 35, 2539-2551.	7.2	51
22	Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. <i>Journal of Hematology and Oncology</i> , 2021, 14, 70.	17.0	25
23	Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (<sc>HMA</sc> or liposomal daunorubicin<sc>CPX</sc>). <i>American Journal of Hematology</i> , 2021, 96, E196-E200.	4.1	10
24	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021, 5, 2481-2489.	5.2	25
25	Efficacy of blinatumomab for MRD relapse in ALL post allogeneic HCT. <i>Leukemia Research</i> , 2021, 104, 106579.	0.8	4
26	Refractory primary autoimmune myelofibrosis treated with ruxolitinib. <i>American Journal of Hematology</i> , 2021, 96, E283-E285.	4.1	3
27	Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2464-2470.	2.4	8
28	Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 125.	6.2	2
29	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). <i>Blood Advances</i> , 2021, 5, 2775-2787.	5.2	15
30	Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 938.e1-938.e6.	1.2	63
31	Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML. <i>Journal of Hematology and Oncology</i> , 2021, 14, 122.	17.0	13
32	Exosome-driven lipolysis and bone marrow niche remodeling support leukemia expansion. <i>Haematologica</i> , 2021, 106, 1484-1488.	3.5	9
33	Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance. <i>Nature Communications</i> , 2021, 12, 6154.	12.8	27
34	Donor derived leukemia in allogeneic transplantation. <i>Leukemia and Lymphoma</i> , 2021, 62, 2823-2830.	1.3	6
35	Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Identifies Immune Modulation As a Key Pathway for Predicting Azacitidine (AZA) Response in Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2021, 138, 3690-3690.	1.4	0
36	Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias. <i>Blood</i> , 2021, 138, 3430-3430.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience. <i>Blood</i> , 2021, 138, 3037-3037.	1.4	0
38	Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. <i>Bone Marrow Transplantation</i> , 2021, , .	2.4	2
39	A Randomized Open Label Pilot Study of <i>Clostridium Butyricum</i> Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 334-334.	1.4	1
40	Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 372-372.	1.4	13
41	Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Predicted Novel Biomarkers for Hyper-CVAD (CVAD) Treatment Response and Combination of Rituximab and Cladribine (RC) in CVAD Resistant Cases of Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2021, 138, 3550-3550.	1.4	0
42	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL. <i>Blood</i> , 2021, 138, 3955-3955.	1.4	0
43	Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance). <i>Blood</i> , 2021, 138, 226-226.	1.4	0
44	Multi-Antigen Primed T Cells Promote Apoptosis of Acute Myeloid Leukemia (AML). <i>Blood</i> , 2021, 138, 4794-4794.	1.4	0
45	Ex vivo isolation, expansion and bioengineering of CCR7+CD95-/or CD62L+CD45RA+ tumor infiltrating lymphocytes from acute myeloid leukemia patients' bone marrow. <i>Neoplasia</i> , 2021, 23, 1252-1260.	5.3	4
46	Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 473-475.	2.4	11
47	Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 292-299.	2.0	13
48	Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 877-883.	2.4	13
49	A novel vitamin D gene therapy for acute myeloid leukemia. <i>Translational Oncology</i> , 2020, 13, 100869.	3.7	10
50	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020, 4, 4945-4954.	5.2	34
51	A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2020, 95, 1457-1465.	4.1	2
52	Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e322-e327.	2.0	32
53	Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 3532-3533.	1.3	5
54	State-Transition Analysis of Time-Sequential Gene Expression Identifies Critical Points That Predict Development of Acute Myeloid Leukemia. <i>Cancer Research</i> , 2020, 80, 3157-3169.	0.9	25

#	ARTICLE	IF	CITATIONS
55	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions. <i>Blood Cancer Discovery</i> , 2020, 1, 48-67.	5.0	30
56	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1425-1432.	2.0	5
57	Iron Overload Is Associated with Delayed Engraftment and Increased Nonrelapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1697-1703.	2.0	6
58	Discovery of proangiogenic CD44 ⁺ mesenchymal cancer stem cells in an acute myeloid leukemia patient's bone marrow. <i>Journal of Hematology and Oncology</i> , 2020, 13, 63.	17.0	10
59	Requirement of GTP binding for TIF ^{90A} -regulated ribosomal RNA synthesis and oncogenic activities in human colon cancer cells. <i>Journal of Cellular Physiology</i> , 2020, 235, 7567-7579.	4.1	4
60	The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement. <i>Leukemia and Lymphoma</i> , 2020, 61, 2020-2023.	1.3	15
61	Venetoclax and hypomethylating agents in <i>FLT3</i> -mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1193-1199.	4.1	28
62	Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1084-1090.	2.0	19
63	Myeloid cell-targeted miR-146a mimic inhibits NF- κ B-driven inflammation and leukemia progression in vivo. <i>Blood</i> , 2020, 135, 167-180.	1.4	88
64	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020, 135, 371-380.	1.4	127
65	Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351). <i>Blood</i> , 2020, 136, 37-38.	1.4	2
66	Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial. <i>Blood</i> , 2020, 136, 49-50.	1.4	2
67	HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML. <i>Aging</i> , 2020, 12, 16759-16774.	3.1	9
68	Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 41-42.	1.4	1
69	Superior Therapy Response Predictions for Patients with Myelodysplastic Syndrome (MDS) Using Cellworks Singula [®] ; Mycare-020-02. <i>Blood</i> , 2020, 136, 9-10.	1.4	0
70	Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 39-39.	1.4	0
71	Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis. <i>Blood</i> , 2020, 136, 21-22.	1.4	0
72	Assessment of Cellworks Omics Biosimulation Therapy Response Predictions for Patients with Acute Myeloid Leukemia (AML) Using Cellworks Singula [®] ; Mycare-020-01. <i>Blood</i> , 2020, 136, 35-35.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Microrna-142 Deficiency Promotes Chronic Myeloid Leukemia (CML) Transformation from Chronic Phase (CP) to Blast Crisis (BC). <i>Blood</i> , 2020, 136, 4-4.	1.4	0
74	Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 41-42.	1.4	3
75	Repurposing Nelarabine to Induce Differentiation of Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 26-26.	1.4	0
76	Venetoclax Synergizes with the RNA-Directed Nucleoside Analog 8-Chloro-Adenosine in Acute Myeloid Leukemia in Vitro and In Vivo. <i>Blood</i> , 2020, 136, 22-23.	1.4	0
77	Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use. <i>American Journal of Hematology</i> , 2019, 94, 358-362.	4.1	46
78	Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia. <i>Blood</i> , 2019, 134, 1257-1268.	1.4	30
79	PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ acute myeloid leukemia. <i>Blood</i> , 2019, 134, 548-560.	1.4	58
80	The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies. <i>Leukemia Research</i> , 2019, 84, 106196.	0.8	5
81	Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E253-E255.	4.1	62
82	Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation. <i>Leukemia Research</i> , 2019, 87, 106230.	0.8	9
83	Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 187, e45-e48.	2.5	49
84	Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e400-e405.	0.4	12
85	ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model. <i>Blood</i> , 2019, 134, 432-444.	1.4	32
86	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. <i>Leukemia</i> , 2019, 33, 2599-2609.	7.2	76
87	Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing. <i>Cancer Genetics</i> , 2019, 235-236, 31-38.	0.4	23
88	Ebp1 p48 promotes oncogenic activities in human colon cancer cells through regulation of TIF1-mediated ribosomal RNA synthesis. <i>Journal of Cellular Physiology</i> , 2019, 234, 17612-17621.	4.1	9
89	8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia. <i>Journal of Cellular Physiology</i> , 2019, 234, 16295-16303.	4.1	12
90	Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting. <i>Blood Advances</i> , 2019, 3, 1027-1032.	5.2	14

#	ARTICLE	IF	CITATIONS
91	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i> , 2019, 133, 1548-1559.	1.4	292
92	The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML. <i>Journal of Cellular Physiology</i> , 2019, 234, 14040-14049.	4.1	50
93	MiR-16 regulates crosstalk in NF- κ B tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. <i>JCI Insight</i> , 2019, 4, .	5.0	33
94	Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis. <i>Blood</i> , 2019, 134, 4518-4518.	1.4	1
95	More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine. <i>Chinese Clinical Oncology</i> , 2019, 8, S25-S25.	1.2	6
96	Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 721-749.	4.9	314
97	Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. <i>Nature Medicine</i> , 2018, 24, 450-462.	30.7	123
98	A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. <i>Haematologica</i> , 2018, 103, 982-987.	3.5	16
99	Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, e404-e407.	3.5	212
100	The role of ErbB3 binding protein 1 in cancer: Friend or foe?. <i>Journal of Cellular Physiology</i> , 2018, 233, 9110-9120.	4.1	20
101	Aging in a Relativistic Biological Space-Time. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 55.	3.7	4
102	Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1828-1835.	2.0	15
103	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (CBF-TJ ETQ ₀₁). <i>Journal of Cellular Physiology</i> , 2018, 233, 9110-9120.	2.8	17
104	SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. <i>Cell Stem Cell</i> , 2018, 23, 355-369.e9.	11.1	68
105	Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to <i>de novo</i> acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. <i>Haematologica</i> , 2018, 103, 1662-1668.	3.5	41
106	Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in Adults. <i>Blood</i> , 2018, 132, 1552-1552.	1.4	3
107	CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies. <i>Blood</i> , 2018, 132, 1408-1408.	1.4	19
108	Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes. <i>Blood</i> , 2018, 132, 3416-3416.	1.4	1

#	ARTICLE	IF	CITATIONS
109	MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis. <i>Blood</i> , 2018, 132, 1752-1752.	1.4	0
110	Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study. <i>Blood</i> , 2018, 132, 2170-2170.	1.4	0
111	Cytokine Gene Polymorphisms Are Associated with Disease Response to Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 1549-1549.	1.4	0
112	Effect of Vancomycin-Resistance Enterococci Colonization Status Prior to Allogeneic Hematopoietic Cell Transplantation on Transplant Outcomes: A Single Center Retrospective Experience. <i>Blood</i> , 2018, 132, 3386-3386.	1.4	0
113	Antileukemic Activity of 8-Chloro-Adenosine (8-Cl-Ado) Is Mediated By Mir-155 Degradation and ErbB3 Binding Protein (Ebp1)-Dependent p53 Activation: A Novel Therapeutic Approach for FLT3-ITD Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 3938-3938.	1.4	0
114	Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation. <i>Blood</i> , 2018, 132, 2181-2181.	1.4	0
115	Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 618-624.	2.0	84
116	Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 858-865.	4.1	126
117	Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia. <i>Leukemia Research</i> , 2017, 59, 124-135.	0.8	22
118	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 454-464.	27.0	1,628
119	HDAC8 regulates long-term hematopoietic stem-cell maintenance under stress by modulating p53 activity. <i>Blood</i> , 2017, 130, 2619-2630.	1.4	41
120	Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status. <i>Haematologica</i> , 2017, 102, 2030-2038.	3.5	26
121	Philadelphia chromosome as a recurrent event among therapy-related acute leukemia. <i>American Journal of Hematology</i> , 2017, 92, E18-E19.	4.1	11
122	Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1212-1217.	2.0	12
123	Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. <i>Blood</i> , 2016, 127, 1687-1700.	1.4	70
124	Not only TKI! Targeting FLT3-ITD by autophagy. <i>Blood</i> , 2016, 127, 796-797.	1.4	1
125	Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. <i>Blood</i> , 2016, 127, 2879-2889.	1.4	80
126	CBF β -SMMHC creates aberrant megakaryocyte-erythroid progenitors prone to leukemia initiation in mice. <i>Blood</i> , 2016, 128, 1503-1515.	1.4	21

#	ARTICLE	IF	CITATIONS
127	Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. <i>Cancer Discovery</i> , 2016, 6, 986-1005.	9.4	79
128	A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancer Cell</i> , 2016, 30, 764-778.	16.8	116
129	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2016, 48, 1481-1489.	21.4	231
130	Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 214-214.	1.4	1
131	CCND1 Mutations Increase Protein Stability and Promote Ibrutinib Resistance in Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 4094-4094.	1.4	2
132	HDAC8 Regulates Long-Term Hematopoietic Stem Cell Quiescence and Maintenance. <i>Blood</i> , 2016, 128, 1468-1468.	1.4	1
133	Philadelphia (Ph) Chromosome (BCR-ABL1 fusion) As a Recurrent Genetic Abnormality Among Therapy-Related Acute Leukemia. <i>Blood</i> , 2016, 128, 3974-3974.	1.4	0
134	A Multivariate Clinical and Economic Model for Predicting Risk-Based Costs of Care for Acute Leukemia (AL) Patients (Pts) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT). <i>Blood</i> , 2016, 128, 3547-3547.	1.4	0
135	Potential Targeting Ph+ Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity. <i>Blood</i> , 2016, 128, 2909-2909.	1.4	2
136	Time Sequential Transcriptome Analysis Identifies Mir-126 As an Early Biomarker for Inv(16) Acute Myeloid Leukemia (AML) Disease Progression. <i>Blood</i> , 2016, 128, 773-773.	1.4	0
137	EGFL7 Antagonizes NOTCH Signaling, Stimulates Blast Proliferation and Confers Poor Prognosis in Cytogenetically-Normal Acute Myeloid Leukemia (CN-AML). <i>Blood</i> , 2016, 128, 2689-2689.	1.4	0
138	8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth and Synergizes with the BCL-2 Inhibitor Venetoclax (ABT-199). <i>Blood</i> , 2016, 128, 2758-2758.	1.4	0
139	Acute Myeloid Leukemia: Biologic, Prognostic, and Therapeutic Insights. <i>Oncology</i> , 2016, 30, 318-29.	0.5	31
140	HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation. <i>Cell Stem Cell</i> , 2015, 17, 597-610.	11.1	75
141	Preclinical Development of LNA Antimir-155 (MRC-106) in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3802-3802.	1.4	5
142	Proteomics Profiling of Leukemia Derived Exosomes: A Potential Role in Leukemic Transformation. <i>Blood</i> , 2015, 126, 3857-3857.	1.4	2
143	Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells. <i>Blood</i> , 2015, 126, 51-51.	1.4	2
144	Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1743-1743.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1979-1990.	4.1	49
146	Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: <i>miR-155</i> Upregulation Independently Identifies High-Risk Patients. <i>Journal of Clinical Oncology</i> , 2013, 31, 2086-2093.	1.6	165
147	Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. <i>Blood</i> , 2012, 120, 1130-1136.	1.4	74
148	The prognostic and functional role of microRNAs in acute myeloid leukemia. <i>Blood</i> , 2011, 117, 1121-1129.	1.4	247
149	<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2348-2355.	1.6	699
150	Regulation of Acute Graft-Versus-Host Disease by MicroRNA-155. <i>Blood</i> , 2010, 116, 245-245.	1.4	0
151	MicroRNA expression in acute myeloid leukemia. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 83-88.	2.3	44
152	MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 239-248.	1.7	26
153	Molecular markers in acute myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, 448-51.	0.3	3
154	Introduction: Acute Myeloid Leukemia. <i>Seminars in Oncology</i> , 2008, 35, 324-325.	2.2	8
155	MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2008, 358, 1919-1928.	27.0	427
156	Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, <i>CEBPA</i> Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 5078-5087.	1.6	294
157	MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. <i>Blood</i> , 2008, 111, 3183-3189.	1.4	575
158	FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. <i>Blood</i> , 2008, 111, 1552-1559.	1.4	243
159	Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34+/CD38 ⁺ Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL ⁻ independent Signals. <i>Blood</i> , 2008, 112, 189-189.	1.4	10
160	A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation. <i>Blood</i> , 2008, 112, 3169-3169.	1.4	0
161	High Expression Levels of the ETS-Related Gene, <i>ERG</i> , Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3337-3343.	1.6	184
162	Hyperglycemia in Patients with Acute Myeloid Leukemia Is Associated with Increased Hospital Mortality.. <i>Blood</i> , 2006, 108, 5515-5515.	1.4	3

#	ARTICLE	IF	CITATIONS
163	Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. <i>Current Opinion in Hematology</i> , 2005, 12, 68-75.	2.5	110
164	Overexpression of the ETS-Related Gene, <i>ERG</i> , Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 9234-9242.	1.6	226
165	Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5705-5717.	1.6	324
166	Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. <i>Blood</i> , 2003, 101, 425-432.	1.4	221
167	Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. <i>Clin. Cancer Res.</i> , 9: 1333-1337, 2003. <i>Clinical Cancer Research</i> , 2003, 9, 1248-52.	7.0	28